If you have been following our coverage on this story – Intellectual Property Rights in India along with the CD explains article written on the same link, you would be aware of a latest development –
After releasing our National IPR Policy, our commerce minister, Nirmala Sitharaman maintained that –
India does not recognise “unilateral measures” such as the U.S. Special 301 Report that tries to create pressure on countries to enhance IPR protection beyond the World Trade Organisation’s Agreement on Trade-Related Aspects of IPRs (TRIPS).
So, this is a classic case of Uncle Sam bullying the minions with its internal reports!
Being in the PWL, India does not have much to fear and that probably is the reason why we could make bold statements like the one above! We have been a PWL since the inception of the report, which begs an inquiry into what’s the issue with India’s IPR and USTR?
#1. In 2016, the United States continues to prioritize making progress on IPR issues through the High Level Working Group on Intellectual Property (IP Working Group), established by President Obama and Prime Minister Modi
#2. The 2015 passage of the Commercial Courts, Commercial Division and Commercial Appellate Division of High Courts Bill may provide an important new tool for new patent and trademark applications
#3. Acknowledged and applauded the establishment of India’s first anti-piracy policy unit in Telangana and Andhra Pradesh’s anti-piracy campaign, which resulted in the arrest of 11 individuals
#4. Welcomed the deliberate and transparent process employed in India’s evaluation of a compulsory license application in 2015
Q1. One of the reasons why USTR included India under the “priority watchlist” in its Special 301 report:
Q2. Which of the following statements are correct?
Q3.Correct statements about “Compulsory License” in Patent law?
Q4. Incorrect statements about “Ever Greening” in Patent law?
Q5. Indian Patent Controller General gave compulsory license to NATCO to manufacture Bayer pharma’s anti-cancer drug “Nexvar”, because _____.
Q6. Novartis lost patent right over its anti-cancer drug Glivec in India, because ____.
Published with inputs from Gaurav